Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study-Reference-Cited by-同舟云学术

Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study

Published:2023-09-08 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Pla-Juher Helena^ORCID,Pardo Marta,Izquierdo Àngel J.,Darder Esther,Carbó Anna,Munté Elisabet,Torres-Esquius Sara,Balmaña Judith,Lázaro Concepción,Brunet Joan M.,Barretina-Ginesta Maria-Pilar

Abstract

Abstract Objective To know the risk of endometrial cancer (EC) in a population of women with BRCA 1/2 pathogenic or likely pathogenic variants after risk-reducing salpingo-oophorectomy (RRSO). Methods The study cohort included data from 857 women with BRCA mutations who underwent RRSO visited four hospitals in Catalonia, Spain, from January 1, 1999 to April 30, 2019. Standardized incidence ratio (SIR) of EC was calculated in these patients using data from a regional population-based cancer registry. Results After RRSO, eight cases of EC were identified. Four in BRCA 1 carriers and four in BRCA2 carriers. The expected number of cases of EC was 3.67 cases, with a SIR of 2.18 and a 95% CI (0.93–3.95). Conclusions In our cohort, the risk of EC in BRCA1/2 carriers after RRSO is not greater than expected. Hysterectomy is not routinely recommended for these patients.

Funder

Universitat de Girona

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12094-023-03312-4.pdf

Reference26 articles.

1. Nair N, Schwarts M, Guzzardi L, Durlester N, Pan S, Overbey J, et al. Hysterectomy at the time of risk-reducing surgery in BRCA carriers. Gynecol Oncol Rep. 2018;26(October):71–4. https://doi.org/10.1016/j.gore.2018.10.003.

2. Domchek SM, Freibel TM, Singer C, Evans G, Lynch H, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. J Am Med Assoc. 2010;304(9):967–75. https://doi.org/10.1001/jama.2010.1237.Association.

3. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing Salpingo–Oophorectomy in women with a BRCA1 or BRCA2 mutation. Obstet Gynecol Surv. 2002;57(9):574–5. https://doi.org/10.1097/00006254-200209000-00016.

4. Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol. 2016;27(Supplement 5):v103–10. https://doi.org/10.1093/annonc/mdw327.

5. Finch APM, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32(15):1547–53. https://doi.org/10.1200/JCO.2013.53.2820.